CN116261561B - 某些化学组合物及其使用方法 - Google Patents

某些化学组合物及其使用方法

Info

Publication number
CN116261561B
CN116261561B CN202180059974.5A CN202180059974A CN116261561B CN 116261561 B CN116261561 B CN 116261561B CN 202180059974 A CN202180059974 A CN 202180059974A CN 116261561 B CN116261561 B CN 116261561B
Authority
CN
China
Prior art keywords
amino
compound
methyl
alkyl
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180059974.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN116261561A (zh
Inventor
安德烈·W·康拉迪
黄春浩
李克川
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aoji Biotechnology Co ltd
Original Assignee
Aoji Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aoji Biotechnology Co ltd filed Critical Aoji Biotechnology Co ltd
Publication of CN116261561A publication Critical patent/CN116261561A/zh
Application granted granted Critical
Publication of CN116261561B publication Critical patent/CN116261561B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202180059974.5A 2020-05-15 2021-05-14 某些化学组合物及其使用方法 Active CN116261561B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063025474P 2020-05-15 2020-05-15
US63/025,474 2020-05-15
PCT/US2021/032495 WO2021231892A1 (en) 2020-05-15 2021-05-14 Certain chemical compositions and methods of use thereof

Publications (2)

Publication Number Publication Date
CN116261561A CN116261561A (zh) 2023-06-13
CN116261561B true CN116261561B (zh) 2025-10-31

Family

ID=76270111

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180059974.5A Active CN116261561B (zh) 2020-05-15 2021-05-14 某些化学组合物及其使用方法

Country Status (12)

Country Link
US (2) US11591322B2 (https=)
EP (1) EP4149941B1 (https=)
JP (1) JP2023526332A (https=)
KR (1) KR20230051127A (https=)
CN (1) CN116261561B (https=)
AU (1) AU2021273072A1 (https=)
BR (1) BR112022023199A2 (https=)
CA (1) CA3178813A1 (https=)
ES (1) ES3054109T3 (https=)
IL (1) IL298219A (https=)
MX (1) MX2022014356A (https=)
WO (1) WO2021231892A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3054109T3 (en) 2020-05-15 2026-01-29 Algen Biotechnologies Inc Certain chemical compositions and methods of use thereof
WO2023086417A1 (en) * 2021-11-11 2023-05-19 Algen Biotechnologies, Inc. Compounds and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103339110A (zh) * 2011-01-28 2013-10-02 诺瓦提斯公司 作为cdk9抑制剂的取代的杂-联芳基化合物及其用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4932412A (en) 1986-12-18 1990-06-12 Immunomedics, Inc. Intraoperative and endoscopic tumor detection and therapy
EP1223952B1 (en) 1999-10-07 2008-04-16 Carlos Estuardo Aguilar-Cordova Methods for treatment of solid tumors and metastasis by gene therapy
WO2004110350A2 (en) 2003-05-14 2004-12-23 Torreypines Therapeutics, Inc. Compouds and uses thereof in modulating amyloid beta
WO2006071958A1 (en) 2004-12-29 2006-07-06 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
US8415381B2 (en) 2009-07-30 2013-04-09 Novartis Ag Heteroaryl compounds and their uses
WO2012101065A2 (en) * 2011-01-28 2012-08-02 Novartis Ag Pyrimidine biaryl amine compounds and their uses
WO2012101063A1 (en) * 2011-01-28 2012-08-02 Novartis Ag N-acyl pyridine biaryl compounds and their uses
WO2012101066A1 (en) 2011-01-28 2012-08-02 Novartis Ag Pyridine biaryl amine compounds and their uses
US9013997B2 (en) 2012-06-01 2015-04-21 Broadcom Corporation System for performing distributed data cut-through
EP3126525B1 (en) 2014-04-04 2020-02-19 Memorial Sloan-Kettering Cancer Center Method and kits for identifying of cdk9 inhibitors for the treatment of cancer
NZ734082A (en) 2015-01-20 2019-01-25 Boehringer Ingelheim Animal Health Usa Inc Anthelmintic compounds, compositions and method of using thereof
PL3429591T3 (pl) 2016-03-16 2023-07-17 Kura Oncology, Inc. Podstawione pochodne tieno[2,3-d]pirymidyny jako inhibitory meniny-mll i metody ich zastosowania
EP3874045A4 (en) 2018-10-31 2022-09-07 The Regents of The University of California Methods and kits for identifying cancer treatment targets
CN114025772A (zh) 2019-04-24 2022-02-08 纪念斯隆凯特琳癌症中心 用于治疗ras突变体癌症的组合物和方法
JP7677914B2 (ja) 2019-06-21 2025-05-15 アルゲン バイオテクノロジーズ，インク． 標的遺伝子を特定するための方法およびシステム
EP4126918A4 (en) 2020-03-31 2024-05-29 The Regents of the University of California COMPOSITIONS AND METHODS FOR IDENTIFYING HOST CELL TARGET PROTEINS FOR THE TREATMENT OF RNA VIRUS INFECTIONS
ES3054109T3 (en) 2020-05-15 2026-01-29 Algen Biotechnologies Inc Certain chemical compositions and methods of use thereof
EP4185867A4 (en) 2020-07-22 2024-08-07 Algen Biotechnologies, Inc. Methods and systems for determining drug effectiveness
WO2023086417A1 (en) 2021-11-11 2023-05-19 Algen Biotechnologies, Inc. Compounds and methods of use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103339110A (zh) * 2011-01-28 2013-10-02 诺瓦提斯公司 作为cdk9抑制剂的取代的杂-联芳基化合物及其用途

Also Published As

Publication number Publication date
CN116261561A (zh) 2023-06-13
US20220289725A1 (en) 2022-09-15
US20230295135A1 (en) 2023-09-21
EP4149941A1 (en) 2023-03-22
CA3178813A1 (en) 2021-11-18
US12264152B2 (en) 2025-04-01
AU2021273072A1 (en) 2022-12-15
BR112022023199A2 (pt) 2023-04-04
KR20230051127A (ko) 2023-04-17
ES3054109T3 (en) 2026-01-29
IL298219A (en) 2023-01-01
US11591322B2 (en) 2023-02-28
JP2023526332A (ja) 2023-06-21
MX2022014356A (es) 2023-03-09
WO2021231892A1 (en) 2021-11-18
EP4149941B1 (en) 2025-09-03

Similar Documents

Publication Publication Date Title
US11434232B2 (en) ATR inhibitor and application thereof
RU2638540C1 (ru) Ингибиторы днк-пк
TWI672304B (zh) 作爲酪胺酸激酶抑制劑之經取代的乙炔基雜雙環化合物
TW201838966A (zh) 取代的二氫茚－４－甲醯胺及其類似物以及其使用方法
RS62713B1 (sr) Terapeutske kombinacije btk inhibitora i bcl-2 inhibitora
BR112021011147A2 (pt) Benzamidas de derivados de pirazolil-amino-pirimidinila e composições e métodos das mesmas
CN116761799A (zh) 嘧啶并吡喃类化合物
KR20230051528A (ko) 화합물, 조성물 및 방법
TW201936585A (zh) 5-氟尿嘧啶化合物
KR20180094938A (ko) 오피오이드 수용체 리간드와 시토크롬 p450 억제제의 결합
CN116261561B (zh) 某些化学组合物及其使用方法
CN111630047B (zh) 含有羧酸基团的苯并氮杂环类化合物及其制备方法和用途
JP7822308B2 (ja) 固形腫瘍の処置のための組成物
JP2023510865A (ja) 血管脂肪腫の処置のための組成物
KR20220007151A (ko) 브루톤 티로신 키나아제 억제제인 치환된 1-아미노-1h-이미다졸-5-카르복사미드
CN111801322A (zh) 用于治疗中枢和周边神经系统病症的激酶抑制剂
JP2023522866A (ja) ベンジルオキシリン酸エステル（ホスホン酸エステル）化合物
JP2025540292A (ja) ヌクレオチド類似体とその組成物および使用
JP7627269B2 (ja) ＲＯＲγｔ阻害剤、その製造方法及び使用
WO2023086417A1 (en) Compounds and methods of use thereof
RU2799047C2 (ru) Ингибитор atr и его применение
CN109952104A (zh) 二硫etp衍生物
US20230339904A1 (en) Isoindolinones, pharmaceutical compositions, and therapeutic applications
HK40128990A (en) Carbonyl fused heterocyclic derivative used as ubiquitin-specific protease inhibitor
CN121085992A (zh) 信号转导及转录激活蛋白6选择性降解剂化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant